Chromoendoscopy + targeted biopsy (IBD dysplasia surveillance)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-CHROMOENDOSCOPY-DYSPLASIA-IBD |
|---|---|
| Type | Biomarker |
| Aliases | Chromoendoscopy for IBD surveillanceSCENIC chromoendoscopydye-spray chromoendoscopymethylene blue chromoendoscopyХромоендоскопія з прицільною біопсією (нагляд дисплазії при ЗЗК) |
| Status | reviewed 2026-05-18 |
| Diseases | None declared |
| Sources | SRC-NCCN-COLON-2025 |
Biomarker Facts
| Biomarker type | imaging |
|---|---|
| Measurement | MethodHigh-definition white-light colonoscopy + topical methylene blue OR indigo carmine dye spray; targeted biopsy of visible lesions per SCENIC consensus Unitscategorical: dysplasia (visible/invisible, LGD/HGD) | indefinite | negative |
| Related biomarkers | None declared |
Notes
STUB. SCENIC (2015) + AGA/ASGE/ESGE consensus: chromoendoscopy with targeted biopsy is preferred over random 4-quadrant biopsies for dysplasia detection in long-standing UC/Crohn's colitis (≥8 years pancolitis or ≥15 left-sided). Sensitivity gain ~2-3× for flat dysplasia. Triggers surgical referral (colectomy) for invisible HGD or visible non-resectable dysplasia.
Used By
No reverse references found in the YAML corpus.